Blood Clot News and Research RSS Feed - Blood Clot News and Research

A Blood Clot is a mass of blood that forms when blood platelets, proteins, and cells stick together. When a blood clot is attached to the wall of a blood vessel, it is called a thrombus. When it moves through the bloodstream and blocks the flow of blood in another part of the body, it is called an embolus.
Ultrasound-activated microbubbles help preserve healthy heart tissue

Ultrasound-activated microbubbles help preserve healthy heart tissue

Researchers funded by the National Institute of Biomedical Imaging and Bioengineering used ultrasound-activated microbubbles to improve preservation of heart muscle and function in a pig heart attack model. [More]
New blood clotting analysis system could help determine effects antithrombotic (anti-clotting) drugs

New blood clotting analysis system could help determine effects antithrombotic (anti-clotting) drugs

A new blood clotting analysis system designed in Japan makes it easier to determine the effects of taking one or more antithrombotic (anti-clotting) drugs. [More]
Gene therapy holds considerable potential for safe, effective treatment of people with factor VII deficiency

Gene therapy holds considerable potential for safe, effective treatment of people with factor VII deficiency

Hematology researchers have used a single injection of gene therapy to correct a rare bleeding disorder, factor VII deficiency, in dogs. This success in large animals holds considerable potential for a safe, effective and long-lasting new treatment in humans with the same bleeding disorder. [More]
Researchers find association between obesity and VTE in pediatric populations

Researchers find association between obesity and VTE in pediatric populations

Researchers at Wake Forest Baptist Medical Center have found an association between obesity and the formation of blood clots in the veins of children and adolescents. [More]
Middle-aged patients undergoing AVR may fare better with tissue-based valves rather than metal-based valves

Middle-aged patients undergoing AVR may fare better with tissue-based valves rather than metal-based valves

Patients between the ages of 40 and 70 who undergo aortic valve replacement (AVR) may fare better with tissue-based valves rather than metal-based valves, according to a review article posted online today by The Annals of Thoracic Surgery. [More]
Wyss Institute scientists develop better assay for testing hemostasis

Wyss Institute scientists develop better assay for testing hemostasis

Scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University have devised a better assay for testing blood's clotting tendency, also known as hemostasis, which could one day prove lifesaving in a variety of clinical situations in which a patient's health is jeopardized by abnormal blood coagulation and platelet function. [More]
Women suffering from blood clots can safely take hormone replacement therapy with anticoagulants

Women suffering from blood clots can safely take hormone replacement therapy with anticoagulants

New research published online today in Blood, the Journal of the American Society of Hematology (ASH), is the first to demonstrate that women on blood thinners can take estrogen-containing contraception or hormone replacement therapy without an increased risk of blood clots or uterine bleeding. [More]
American College of Cardiology launches new STS/ACC TAVR In-Hospital Mortality Risk App

American College of Cardiology launches new STS/ACC TAVR In-Hospital Mortality Risk App

The American College of Cardiology has launched a new STS/ACC TAVR In-Hospital Mortality Risk App and an extensively overhauled the ACC AnticoagEvaluator App, bolstering its expansive Clinical App Collection. With these new and improved apps, the ACC continues to diversify the clinical content and decision support it offers clinicians in the mobile space. [More]
Study: Preoperative use of blood-thinning drugs associated with decreased risk of blood clots

Study: Preoperative use of blood-thinning drugs associated with decreased risk of blood clots

Among patients undergoing major cancer operations, the preoperative use of blood-thinning drugs such as heparin does not increase rates of major bleeding or transfusions, and is associated with a decreased risk of blood clots, according to new study results published online in the Journal of the American College of Surgeons ahead of print publication early next year. [More]
XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the results from their real-world study XALIA showing that, in people with deep vein thrombosis (DVT), the rates of major bleeding and recurrent blood clots for XARELTO (rivaroxaban) in routine clinical practice were generally consistent with those observed in Phase 3 research. [More]
Boston Scientific obtains FDA approval, CE Mark for AngioJet ZelanteDVT catheter to treat DVT

Boston Scientific obtains FDA approval, CE Mark for AngioJet ZelanteDVT catheter to treat DVT

Boston Scientific has received United States (U.S.) Food and Drug Administration approval and CE Mark for the AngioJet ZelanteDVT thrombectomy catheter to treat deep vein thrombosis (DVT) in large-diameter upper and lower limb peripheral veins. [More]
Isis Pharmaceuticals begins ISIS-FXI Rx Phase 2 study in patients with ESRD on hemodialysis

Isis Pharmaceuticals begins ISIS-FXI Rx Phase 2 study in patients with ESRD on hemodialysis

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 2 study evaluating ISIS-FXIRx in patients with end-stage renal disease (ESRD) on hemodialysis. In May 2015, Isis entered into an exclusive license agreement with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXIRx for the prevention of clotting disorders. [More]
Wyss Institute, UMass team up to develop drug-device combination for treating blood clots in stroke patients

Wyss Institute, UMass team up to develop drug-device combination for treating blood clots in stroke patients

Scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University developing novel nanotherapeutics for clearing obstructed blood vessels have teamed up with researchers at University of Massachusetts' New England Center for Stroke Research (NECSTR) to develop a new, highly effective drug-device combination for treating life-threatening blood clots in patients with stroke. [More]
New tool may help identify high risk atherosclerotic plaques

New tool may help identify high risk atherosclerotic plaques

Researchers have developed and validated a new tool to help identify unstable or high risk atherosclerotic plaques--inflamed fatty deposits in the artery wall and a main contributor to cardiovascular disease (CVD). This breakthrough may lead to better identifying which plaques are considered at the highest risk for rupturing and causing a heart attack or stroke. [More]
FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called chronic immune thrombocytopenic purpura (ITP). Promacta can be used in these children when they have not achieved an appropriate response using other ITP medicines or surgery to remove the spleen. [More]
FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

Salix Pharmaceuticals and Pharming Group NV announced today that the U.S. Food and Drug Administration has granted 12 years of exclusivity to RUCONEST (C1 esterase inhibitor [recombinant]) 50 IU/kg. [More]
Anti-coagulant medications quickly resolve blood clots that could impair valve motion

Anti-coagulant medications quickly resolve blood clots that could impair valve motion

Heart valve replacements made from tissue (bioprosthetic valves) have long been thought to be spared the complication of blood clot formation. Researchers have now found that about 15 percent of all bioprosthetic aortic heart valve patients develop blood clots on the leaflets affecting valve opening, regardless of whether the patient received the new valve via open-heart surgery or a minimally-invasive catheter procedure, a new study from the Cedars-Sinai Heart Institute shows. [More]
New Medicare payment model reduces use of low-value services

New Medicare payment model reduces use of low-value services

In the first large-scale study to assess the effects of the Affordable Care Act's reforms to physician and hospital payments on the use of wasteful health care services, researchers have found that a new Medicare payment model reduced the number of times patients received services providing little or no health benefit. [More]
SLU scientist receives grant to solve blood-clotting mysteries

SLU scientist receives grant to solve blood-clotting mysteries

Last summer, SLU scientists made a breakthrough discovery about the way in which blood clots. Through X-ray crystallography, they solved the molecular structure of prothrombin, an important blood-clotting protein, revealing an unexpected, flexible role for a "linker" region that may be the key to developing better life-saving drugs. [More]
Study: Retrieval of larger thrombi during IAT linked to improved neurological recovery after acute ischaemic stroke

Study: Retrieval of larger thrombi during IAT linked to improved neurological recovery after acute ischaemic stroke

Retrieval of larger thrombi during intra arterial treatment (IAT) is associated with improved neurological recovery after acute ischaemic stroke, according to a sub study of the MR CLEAN trial presented at ESC Congress today by Dr Anouchska Autar, PhD candidate at the Erasmus Medical Centre in Rotterdam, the Netherlands. [More]
Advertisement
Advertisement